On 13 December 2016, the Financial Times (FT) published a letter to the Editor, from EPAD Executive Committee member Dr Jose Luis Molinuevo of the BarcelonaBeta Brain Research Center. The letter was titled “Early intervention is key to tackling Alzheimer’s”. Making reference to the FT editorial “The case for prioritising Alzheimer’s research” of 26 November…
On 29 November, the Slovak Presidency of the European Union organised a conference on “Alzheimer’s disease – epidemic of the third millennium: Are we ready to face it?” in Bratislava, focussing on four key themes discussed by four panels. One of the panels was on “Prevention and Intervention strategies in Alzheimer’s disease” and included a…
Current Alzheimer’s disease (AD) research initiatives focus on cognitively healthy individuals with biomarkers that are associated with the development of AD. It is unclear whether biomarker results should be returned to research participants and what the psychological, behavioural and social effects of disclosure are. A systematic review by the European Prevention of Alzheimer’s Dementia (EPAD)…
On 10 November 2016, the European Prevention of Alzheimer’s Dementia (EPAD) initiative held a public conference in Geneva, Switzerland, in collaboration with Hôpitaux universitaires de Genève (HUG). Approximately 100 delegates attended the French and English-language conference, “Prévenir la maladie d’Alzheimer en Suisse – Un but atteignable“ (Preventing Alzheimer’s disease in Switzerland – A realistic goal).…
What is your current role in EPAD? I am co-chair with Michael Ropacki of the Clinical and Cognitive Outcomes Scientific Advisory Group (CCO-SAG), which is part of WP1. I am also a member of the Epidemiology Advisory Group. The CCO-SAG includes leading neuropsychologists and neurologists from Europe and the USA, and our work has principally…
What is your current role in EPAD? I am the industry co-lead for Work Package 6, together with Jean Georges from Alzheimer Europe. Work Package 6 is the communication and information dissemination engine of EPAD. Our primary purpose is to let the world know what EPAD is doing. Our audience is very broad, ranging from…
We are thrilled to report on recent progress on the European Prevention of Alzheimer’s Dementia (EPAD) study – just as we are nearing the time point when the first follow-up visits are due there have been two key papers that the EPAD consortium have published. The papers published this week summarise current assessment measures that…
Today, our new sister project Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) announces the launch of its novel research initiative, bringing together academic and private research partners to investigate the value of β-amyloid using positron emission tomography (PET) imaging as a diagnostic and therapeutic marker for Alzheimer’s dementia. Beta-amyloid (β-amyloid) deposition in the brain is…
AMYPAD is a European project to establish the true value of amyloid PET in a diagnostic and prognostic setting (http://www.amypad.eu/). This 5-year project is a collaboration between industry (GEHC, Piramal, Janssen, Ixico) and academic partners funded by the IMI-2 program (total budget 27 million euro). Throughout Europe we will recruit 900 memory clinic patients and…
The Innovative medicines Initiative (IMI) Communications Team has developed a factsheet containing information about all of the dementia-related projects they are funding, including EPAD.
It also lists some upcoming IMI projects in the field.
You can view the factsheet here: http://www.imi.europa.eu/sites/default/files/uploads/documents/Publications/IMIdementiaportfolio_factsheet_June2016.pdf
